{
    "clinical_study": {
        "@rank": "88864", 
        "acronym": "NeoEribulin", 
        "arm_group": {
            "arm_group_label": "Eribulin", 
            "arm_group_type": "Experimental", 
            "description": "1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, non-randomized, open-label, multicenter, single-arm exploratory\n      pharmacogenomic study of single agent eribulin as neoadjuvant therapy in patients with\n      operable Stage III HER2 non-overexpressing breast cancer."
        }, 
        "brief_title": "Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent, specifically highlighting the molecular characterization of\n             tumor and genomic samples\n\n          -  Age \u226518 years\n\n          -  Histologically confirmed invasive breast carcinoma, with all of the following\n             characteristics:\n\n               -  Primary tumor \u22652cm in largest diameter (cT1-3)\n\n               -  cN0-1\n\n               -  No evidence of distant metastasis (M0)\n\n          -  Breast cancer (BC) eligible for primary surgery\n\n          -  Available pre-treatment core (Tru-cut) biopsy or possibility of performing one\n\n          -  HER2-negative BC (as per local assessment), defined as either of the following:\n\n               -  0-1+ expression by IHC\n\n               -  2+ expression by IHC and in situ hybridization (FISH/CISH) without HER2 gene\n                  amplification (<4 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene\n                  copies to Cr17 signals] of <1.8)\n\n               -  Is situ hybridization (FISH/CISH) without HER2 gene amplification, independently\n                  of IHC\n\n          -  Known hormone receptor (ER/PgR) status (as per local assessment) or the possibility\n             of performing the tests\n\n          -  Known percentage of hormone receptor (ER/PgR) and Ki67-positive tumor cells (as per\n             local assessment), or possibility of performing the tests\n\n          -  In the case of a multifocal tumor, the largest lesion must be \u22652 cm and designated\n             the \"target\" lesion for all subsequent tumor evaluations and HER2-negative status\n             must be documented in all the tumor foci\n\n          -  ECOG performance status of 0 or 1\n\n          -  Laboratory values as follows:\n\n               -  Absolute neutrophil count (ANC) \u22651.5 x 109/L\n\n               -  Platelets count \u2265100 x 109/L\n\n               -  Hemoglobin \u22659 g/dL\n\n               -  Serum bilirubin \u22641.5 time the upper limit of normal (ULN)\n\n               -  Alanine aminotransferase and aspartate aminotransferase (AST) \u22642.5 x ULN\n\n               -  Alkaline phosphatase \u22642.5 x ULN\n\n               -  Serum creatinine \u22641.5 mg/dL or calculated creatinine clearance \u226560 mL/m\n\n          -  Absence of any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule\n\n          -  Ability and willingness to comply with study visits, treatment, testing, and to\n             comply with the protocol\n\n          -  Availability of genomic DNA (via whole blood)\n\n        Exclusion Criteria:\n\n          -  Any prior treatment for primary invasive BC\n\n          -  Metastatic, locally advanced or inflammatory (i.e., Stage III-IV) BC\n\n          -  Bilateral invasive BC\n\n          -  Multicentric BC, defined as the presence of two or more foci of cancer in different\n             quadrants of the same breast\n\n          -  Pre-existing peripheral neuropathy of any grade\n\n          -  Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg)\n\n          -  Clinically significant (i.e., active) cardiovascular disease\n\n          -  Long QT syndrome\n\n          -  Concomitant use of inhibitors of hepatic transport proteins such as organic\n             anion-transporting proteins, P-glycoprotein, multidrug resistant proteins etc\n\n          -  Major medical conditions that might affect study participation (e.g., uncontrolled\n             seizure disorder, uncontrolled pulmonary, renal or hepatic dysfunction, or\n             uncontrolled infection)\n\n          -  Other primary malignant tumors within the previous 5 years, except for adequately\n             controlled limited basal cell carcinoma of the skin or carcinoma in situ of the\n             cervix\n\n          -  Known human immunodeficiency virus(HIV) infection or other active or serious\n             infection requiring IV antibiotics at randomization\n\n          -  Pregnancy or breastfeeding women\n\n          -  Women of childbearing potential(<2 years after the last menstruation) not using\n             effective, non-hormonal means of contraception during the study and for a period of 6\n             months following the last administration of study drug\n\n          -  Administration of any live virus vaccine within 8 weeks preceding study entry\n\n          -  Use of any investigational agent within 30 days of administration of the first dose\n             of study drug or concurrent treatment on another clinical study\n\n          -  Requirement for radiation therapy concurrent with study anticancer treatment\n\n          -  Known hypersensitivity to any of the study drugs or excipients\n\n          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the\n             investigator or designee"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669252", 
            "org_study_id": "SOLTI-1007", 
            "secondary_id": "2012-000394-23"
        }, 
        "intervention": {
            "arm_group_label": "Eribulin", 
            "description": "1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.", 
            "intervention_name": "Eribulin", 
            "intervention_type": "Drug", 
            "other_name": "Halaven(R)"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Eribulin", 
            "Neoadjuvant", 
            "PAM50", 
            "Triple-negative", 
            "Luminal A", 
            "Luminal B"
        ], 
        "lastchanged_date": "February 11, 2013", 
        "link": {
            "description": "SOLTI Breast Cancer Research Group", 
            "url": "http://www.gruposolti.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "doris.augustin@klinikum-deggendorf.de", 
                    "last_name": "Doris Augustin", 
                    "phone": "+49 991 380 31 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Deggendorf", 
                        "country": "Germany", 
                        "zip": "94469"
                    }, 
                    "name": "Klinikum des Landkreises Deggendorf Frauenklinik Mammazentrum"
                }, 
                "investigator": {
                    "last_name": "Doris Augustin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "51067"
                    }, 
                    "name": "Brustzentrum im Krankenhaus K\u00f6ln-Holweide Priv. Doz."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "nadia.harbeck@med.uni-muenchen.de", 
                    "last_name": "Nadia Harbeck", 
                    "phone": "+49 89 7095 7581"
                }, 
                "facility": {
                    "address": {
                        "city": "Munic", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Brustzentrum der Universit\u00e4t M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Nadia Harbeck", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "toralf.reimer@med.uni-rostock.de", 
                    "last_name": "Toralf Reimer", 
                    "phone": "+49 381 4401 4500"
                }, 
                "facility": {
                    "address": {
                        "city": "Rostock", 
                        "country": "Germany", 
                        "zip": "18059"
                    }, 
                    "name": "Klinikum S\u00fcdstadt Rostock, Universit\u00e4tsfrauenklinik und Poliklinik"
                }, 
                "investigator": {
                    "last_name": "Toralf Reimer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sofia Broco", 
                    "phone": "+351 239 400 200"
                }, 
                "facility": {
                    "address": {
                        "city": "Coimbra", 
                        "country": "Portugal", 
                        "zip": "3001-651"
                    }, 
                    "name": "Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE"
                }, 
                "investigator": {
                    "last_name": "Sofia Broco", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mnave@hospitaldaluz.pt", 
                    "last_name": "Monica Nave", 
                    "phone": "+35 92 660 96 49"
                }, 
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal", 
                        "zip": "1500-650"
                    }, 
                    "name": "Hospital da Luz"
                }, 
                "investigator": {
                    "last_name": "Monica Nave", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hrodrigues@ipoporto.min-saude.pt", 
                    "last_name": "Helena Rodrigues", 
                    "phone": "+351225084000", 
                    "phone_ext": "7649"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal", 
                        "zip": "4200-072"
                    }, 
                    "name": "Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE"
                }, 
                "investigator": {
                    "last_name": "Helena Rodrigues", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jacortes@vhebron.net", 
                    "last_name": "Javier Cort\u00e9s Cast\u00e1n", 
                    "phone": "93 489 43 50"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Vall d\u00b4Hebron"
                }, 
                "investigator": {
                    "last_name": "Javier Cortes", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mojeda@santpau.es", 
                    "last_name": "Bel\u00e9n Ojeda", 
                    "phone": "+34 93 556 56 51"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i Sant Pau"
                }, 
                "investigator": {
                    "last_name": "Bel\u00e9n Ojeda", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vortega@vhebron.net", 
                    "last_name": "Vanesa Ortega", 
                    "phone": "+34 605 925 779"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitario Vall d\u00b4Hebron"
                }, 
                "investigator": {
                    "last_name": "Vanesa Ortega", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "eduardo.martinez@hospital2000.net", 
                    "last_name": "Eduardo Mart\u00ednez", 
                    "phone": "+34 964354458"
                }, 
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n", 
                        "country": "Spain", 
                        "zip": "12002"
                    }, 
                    "name": "Complejo Hospitalario de Castell\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Eduardo Mart\u00ednez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00e1ceres", 
                        "country": "Spain", 
                        "zip": "10003"
                    }, 
                    "name": "Complejo Hospitalario San Pedro de Alc\u00e1ntara"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "juahaba@gmail.com", 
                    "last_name": "Juan Rafael De la Haba", 
                    "phone": "+34 957 011 893"
                }, 
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }, 
                    "name": "Hospital Universitario Reina Sofia"
                }, 
                "investigator": {
                    "last_name": "Juan Rafael De la Haba", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denia", 
                        "country": "Spain", 
                        "zip": "03700"
                    }, 
                    "name": "Hospital Marina Salud de Denia"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "oncopsr@yahoo.es", 
                    "last_name": "Pedro S\u00e1nchez Rovira", 
                    "phone": "+34 953 22 03 06"
                }, 
                "facility": {
                    "address": {
                        "city": "Ja\u00e9n", 
                        "country": "Spain", 
                        "zip": "23007"
                    }, 
                    "name": "Complejo Hospitalario de Ja\u00e9n"
                }, 
                "investigator": {
                    "last_name": "Pedro S\u00e1nchez Rovira", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "serafinmorales01@gmail.com", 
                    "last_name": "Seraf\u00edn Morales", 
                    "phone": "+34 973 24 81 00", 
                    "phone_ext": "2806"
                }, 
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain", 
                        "zip": "25198"
                    }, 
                    "name": "Hospital Universitari Arnau de Vilanova de Lleida"
                }, 
                "investigator": {
                    "last_name": "Seraf\u00edn Morales", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "Hospital Universitario Puerta de Hierro de Majadahonda"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitario Cl\u00ednico San Carlos"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "mjnoelia@hotmail.com", 
                    "last_name": "Noelia Mar\u00ednez", 
                    "phone": "+3491 336 82 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Universitario Ramon y Cajal"
                }, 
                "investigator": {
                    "last_name": "Noelia Mar\u00ednez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain", 
                        "zip": "30120"
                    }, 
                    "name": "Hospital Universitario Virgen de la Arrixaca"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "kamillano@grupsagessa.cat", 
                    "last_name": "Kepa Amillano", 
                    "phone": "+34 977 310300", 
                    "phone_ext": "5517"
                }, 
                "facility": {
                    "address": {
                        "city": "Reus", 
                        "country": "Spain", 
                        "zip": "43201"
                    }, 
                    "name": "Hospital Universitari Sant Joan de Reus"
                }, 
                "investigator": {
                    "last_name": "Kepa Amillano", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rafael.lopez.lopez@sergas.es", 
                    "last_name": "Rafael L\u00f3pez", 
                    "phone": "+34981950512"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "Complejo Hospitalario Universitario de Santiago"
                }, 
                "investigator": {
                    "last_name": "Rafael L\u00f3pez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41007"
                    }, 
                    "name": "Hospital Virgen de la Macarena"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "rgonzalezmancha@telefonica.net", 
                    "last_name": "Rosario Gonz\u00e1lez", 
                    "phone": "+34 955 013 068"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }, 
                "investigator": {
                    "last_name": "Rosario Gonz\u00e1lez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jctoral@torrevieja-salud.com", 
                    "last_name": "Juan Carlos Toral", 
                    "phone": "+34 965 721 341", 
                    "phone_ext": "1554"
                }, 
                "facility": {
                    "address": {
                        "city": "Torrevieja", 
                        "country": "Spain", 
                        "zip": "03186"
                    }, 
                    "name": "Hospital de Torrevieja"
                }, 
                "investigator": {
                    "last_name": "Juan Carlos Toral", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46015"
                    }, 
                    "name": "Hospital Arnau de Vilanova de Valencia"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "begobermejo@gmail.com", 
                    "last_name": "Ana Lluch", 
                    "phone": "+34 963862600", 
                    "phone_ext": "51306"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }, 
                    "name": "Hospital Clinico Universitario de Valencia"
                }, 
                "investigator": {
                    "last_name": "Ana Lluch", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lmjaso@yahoo.es", 
                    "last_name": "Raquel Andres", 
                    "phone": "+34976765746"
                }, 
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Universitario Lozano Blesa"
                }, 
                "investigator": {
                    "last_name": "Raquel Andres", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Portugal", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALAVEN\u00ae) as Neoadjuvant Treatment for Operable Stage I-II HER2 Non-overexpressing Breast Cancer.", 
        "overall_contact": {
            "email": "jacortes@vhebron.net", 
            "last_name": "Javier Cort\u00e9s Cast\u00e1n", 
            "phone": "+34 93 489 43 50"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario Vall d\u00b4Hebron", 
                "last_name": "Javier Cort\u00e9s, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vall d\u00b4Hebron Institut d\u00b4Oncologia", 
                "last_name": "Aleix Prat, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pCRB , defined as the complete absence of invasive carcinoma in the breast on  histological  examination  at  the  time  of  definitive  surgery,  according  to  the NSABP guidelines", 
            "measure": "Correlation of pre-treatment relative abundance of hundreds of mRNA transcripts from primary breast tumors with pCRB after neoadjuvant treatment with eribulin.", 
            "safety_issue": "No", 
            "time_frame": "At the time of definitive surgery."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of pCRB, defined as the complete absence of invasive carcinoma in the breast on histological examination at the time of definitive surgery, according to the NSABP guidelines.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Rate of pCRBL, defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination at the time of definitive surgery.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Clinical and radiological ORR, defined by RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Correlation of mRNA expression in breast tumors with clinical and radiological ORR at different time points during the neoadjuvant treatment with eribulin.", 
                "safety_issue": "No", 
                "time_frame": "Up to 21 weeks"
            }, 
            {
                "measure": "Rate of pCRB according to breast cancer subtype: Luminal A, Luminal B, Basal-like, HER2-enriched and Claudin-low.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Rate of pCRB according to breast cancer subtype determined by immunohistochemistry (following the 2011 St. Gallen definitions): Luminal A, Luminal B, and TNBC.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Proportion of patients able to have breast conservation surgery after being treated with eribulin as neoadjuvant therapy.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "The correlation between alternations in tubulin isotype expression and mutational status in pre-treatment samples with efficacy parameters, such as pCRB, ORR and BOR.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "The correlation between exome or genome sequencing data from pre-treatment samples with pCRB after neoadjuvant treatment with eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Changes in gene expression and gene mutational status between the pre-treatment samples and samples after treatment.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Number of participants with AEs and serious AEs (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 21 weeks"
            }, 
            {
                "measure": "Percentage of patients who had neutropenia Grade 3-4", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 21 weeks"
            }, 
            {
                "measure": "Percentage of subjects with neuropathy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 21 weeks"
            }, 
            {
                "measure": "Incidence of dose reductions and/or dose delays due to treatment toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 71 days"
            }, 
            {
                "measure": "Analysis of the expression of mRNA from breast tumors", 
                "safety_issue": "No", 
                "time_frame": "At screening"
            }, 
            {
                "measure": "Analysis of the expression of mRNA from breast tumors", 
                "safety_issue": "No", 
                "time_frame": "At 21 days"
            }, 
            {
                "measure": "Analysis of the expression of mRNA from breast tumors", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Correlation of mRNA expression in breast tumors after 21 days of neoadjuvant treatment and at surgery with pCRB.", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery"
            }, 
            {
                "measure": "Sensitivity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At screening"
            }, 
            {
                "measure": "Sensitivity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At 21 days"
            }, 
            {
                "measure": "Sensitivity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At time of definitive surgery"
            }, 
            {
                "measure": "Specificity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At screening"
            }, 
            {
                "measure": "Specificity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At 21 days"
            }, 
            {
                "measure": "Specificity of the gene expression analysis of samples to predict clinical response to eribulin.", 
                "safety_issue": "No", 
                "time_frame": "At time of definitive surgery"
            }
        ], 
        "source": "SOLTI Breast Cancer Research Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Eisai Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SOLTI Breast Cancer Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}